Lung Cancer ESMO 2020 Expert Perspective and Strategic Insights

Expert perspectives and strategic insights on the latest therapeutic developments and translational research coming out of ESMO 2020 regarding lung cancer treatment. Main focus areas: immunotherapy in NSCLC and mesothelioma, oncogenic drivers, and small cell lung cancer

September 21 & 23, 2020
Corey Langer MD Scientific Leader Faculty Chair Aptitude Health


Corey Langer, MD, FACP

University of Pennsylvania, US

Faculty Members

Benjamin Besse, MD, PhD
Institute Gustave Roussy, Villejuif, France

Julie Brahmer, MD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, US

Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain

Marina Garassino, MD
Istituto Nazionale dei Tumori, Milan, Italy

Nasser Hanna, MD
Indiana University School of Medicine, Indianapolis, IN, US

Jyoti Patel, MD
Northwestern University, Evanston, IL, US

Solange Peters, MD, PhD
University Hospital of Lausanne, Switzerland

David Spigel, MD
Sarah Cannon Research Institute, Nashville, TN, US

Sample Report

Start discovering the insights

View Report


The report includes recommendations and key takeaways on

  • Immunotherapy in Stage I–III NSCLC
  • Immunotherapy in Stage IV NSCLC
  • Biomarkers for Immunotherapy in NSCLC
  • EGFR Inhibition (resectable and metastatic NSCLC)
  • Targeting Other Gene Mutations (BRAF, MET, HER2, KRAS)
  • Targeting Gene Fusions (ALK, ROS1, RET, NTRK)
  • Evolving Standards in SCLC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.